The precision with which physicians plan prostate cancer treatment could dramatically improve with the integration of advanced molecular imaging from the moment of diagnosis. Rather than relying solely on traditional MRI scans, this enhanced approach promises to spare some men from unnecessary aggressive interventions while ensuring others receive appropriately intensified care. The DEPROMP trial tracked 230 men with suspected prostate cancer through a comprehensive diagnostic pathway combining 68Ga-PSMA-11 PET/CT with multiparametric MRI before biopsy. Among the 137 men ultimately diagnosed with cancer, the addition of PSMA PET/CT imaging altered treatment recommendations in 34% of cases compared to MRI-only assessments. The most frequent modifications involved surgical planning decisions: 16% had lymph node dissection recommendations changed, 18% saw adjustments to nerve-sparing procedures, and 28% required radiation field modifications. Remarkably, treatment intensification occurred equally in intermediate-risk and high-risk patients, suggesting the technology reveals clinically meaningful disease extent regardless of initial risk stratification. This represents a significant advance in personalized prostate cancer management, where treatment decisions have historically relied on relatively crude risk assessment tools. The high inter-rater agreement among reviewing physicians suggests the imaging findings provide clear, actionable information rather than ambiguous data. However, the study's limitation lies in its focus on treatment planning rather than long-term outcomes. While changing one-third of treatment plans sounds impressive, the ultimate measure will be whether these imaging-guided modifications translate to better cancer control and reduced side effects over years of follow-up.